231 related articles for article (PubMed ID: 33060121)
21. Recent developments in prognostic and predictive testing in uveal melanoma.
Field MG; Harbour JW
Curr Opin Ophthalmol; 2014 May; 25(3):234-9. PubMed ID: 24713608
[TBL] [Abstract][Full Text] [Related]
22. Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and/or metastatic tumors.
Némati F; Sastre-Garau X; Laurent C; Couturier J; Mariani P; Desjardins L; Piperno-Neumann S; Lantz O; Asselain B; Plancher C; Robert D; Péguillet I; Donnadieu MH; Dahmani A; Bessard MA; Gentien D; Reyes C; Saule S; Barillot E; Roman-Roman S; Decaudin D
Clin Cancer Res; 2010 Apr; 16(8):2352-62. PubMed ID: 20371695
[TBL] [Abstract][Full Text] [Related]
23. Systemic treatment of metastatic uveal melanoma: review of literature and future perspectives.
Buder K; Gesierich A; Gelbrich G; Goebeler M
Cancer Med; 2013 Oct; 2(5):674-86. PubMed ID: 24403233
[TBL] [Abstract][Full Text] [Related]
24. Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways.
Wu X; Li J; Zhu M; Fletcher JA; Hodi FS
Mol Cancer Ther; 2012 Sep; 11(9):1905-14. PubMed ID: 22653968
[TBL] [Abstract][Full Text] [Related]
25. Targeted therapy for uveal melanoma.
Triozzi PL; Eng C; Singh AD
Cancer Treat Rev; 2008 May; 34(3):247-58. PubMed ID: 18226859
[TBL] [Abstract][Full Text] [Related]
26. Recent advances in uveal melanoma treatment.
Álvarez-Rodríguez B; Latorre A; Posch C; Somoza Á
Med Res Rev; 2017 Nov; 37(6):1350-1372. PubMed ID: 28759124
[TBL] [Abstract][Full Text] [Related]
27. The Anti-malarial Drug Artesunate Blocks Wnt/β-catenin Pathway and Inhibits Growth, Migration and Invasion of Uveal Melanoma Cells.
Zheng L; Pan J
Curr Cancer Drug Targets; 2018; 18(10):988-998. PubMed ID: 29692251
[TBL] [Abstract][Full Text] [Related]
28. [Multidrug resistance in uveal melanoma].
Gambrelle J; Labialle S; Dayan G; Gayet L; Barakat S; Michaud M; Grange JD; Baggetto LG
J Fr Ophtalmol; 2005 Jun; 28(6):652-9. PubMed ID: 16141933
[TBL] [Abstract][Full Text] [Related]
29. Identification of novel chemotherapeutic strategies for metastatic uveal melanoma.
Fagone P; Caltabiano R; Russo A; Lupo G; Anfuso CD; Basile MS; Longo A; Nicoletti F; De Pasquale R; Libra M; Reibaldi M
Sci Rep; 2017 Mar; 7():44564. PubMed ID: 28303962
[TBL] [Abstract][Full Text] [Related]
30. New therapeutic agents in uveal melanoma.
Velho TR; Kapiteijn E; Jager MJ
Anticancer Res; 2012 Jul; 32(7):2591-8. PubMed ID: 22753717
[TBL] [Abstract][Full Text] [Related]
31. Synergistic growth inhibition based on small-molecule p53 activation as treatment for intraocular melanoma.
de Lange J; Ly LV; Lodder K; Verlaan-de Vries M; Teunisse AF; Jager MJ; Jochemsen AG
Oncogene; 2012 Mar; 31(9):1105-16. PubMed ID: 21765463
[TBL] [Abstract][Full Text] [Related]
32. Clinical Characteristics of Uveal Melanoma in Patients With Germline BAP1 Mutations.
Gupta MP; Lane AM; DeAngelis MM; Mayne K; Crabtree M; Gragoudas ES; Kim IK
JAMA Ophthalmol; 2015 Aug; 133(8):881-7. PubMed ID: 25974357
[TBL] [Abstract][Full Text] [Related]
33. Uveal melanoma: physiopathology and new in situ-specific therapies.
Souto EB; Zielinska A; Luis M; Carbone C; Martins-Gomes C; Souto SB; Silva AM
Cancer Chemother Pharmacol; 2019 Jul; 84(1):15-32. PubMed ID: 31079217
[TBL] [Abstract][Full Text] [Related]
34. Tebentafusp for the treatment of metastatic uveal melanoma.
Schank TE; Hassel JC
Future Oncol; 2022 Apr; 18(11):1303-1311. PubMed ID: 35172589
[TBL] [Abstract][Full Text] [Related]
35. Uveal melanoma: evidence for adjuvant therapy.
Choudhary MM; Triozzi PL; Singh AD
Int Ophthalmol Clin; 2015; 55(1):45-51. PubMed ID: 25436492
[No Abstract] [Full Text] [Related]
36. The biology and management of uveal melanoma.
Sato T; Han F; Yamamoto A
Curr Oncol Rep; 2008 Sep; 10(5):431-8. PubMed ID: 18706273
[TBL] [Abstract][Full Text] [Related]
37. Devising two-stage and multistage phase II studies on systemic adjuvant therapy for uveal melanoma.
Whitehead J; Tishkovskaya S; O'Connor J; Damato B
Invest Ophthalmol Vis Sci; 2012 Jul; 53(8):4986-9. PubMed ID: 22743326
[TBL] [Abstract][Full Text] [Related]
38. Loss of BAP1 expression is associated with an immunosuppressive microenvironment in uveal melanoma, with implications for immunotherapy development.
Figueiredo CR; Kalirai H; Sacco JJ; Azevedo RA; Duckworth A; Slupsky JR; Coulson JM; Coupland SE
J Pathol; 2020 Apr; 250(4):420-439. PubMed ID: 31960425
[TBL] [Abstract][Full Text] [Related]
39. Monosomy 3 Is Linked to Resistance to MEK Inhibitors in Uveal Melanoma.
Mergener S; Siveke JT; Peña-Llopis S
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201614
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of oncogenic cysteinyl leukotriene receptor 2 as a therapeutic target for uveal melanoma.
Slater K; Hoo PS; Buckley AM; Piulats JM; Villanueva A; Portela A; Kennedy BN
Cancer Metastasis Rev; 2018 Sep; 37(2-3):335-345. PubMed ID: 30094568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
